ArticleCellular oncology (Dordrecht, Netherlands)2026
STT3A-mediated FCN3 N-glycosylation promotes Treg cell activation to drive hepatocellular carcinoma progression via Wnt/β-catenin.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- N-glycans in non-malignant tumor microenvironment cells dampen CAR-T cell function in solid tumors.Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide. While regulatory T (Treg) cells are known to contribute to HCC progression, the molecular mechanisms regulating their activation, particularly those involving post-translational modifications, remain poorly understood.
methodsThis study employed a comprehensive approach combining clinical sample analysis, in vitro cell models (HepG2, Hep3B, HCC-LM3) and in vivo xenograft experiments. Genetic manipulation involved lentiviral-mediated knockdown or overexpression of FCN3 and STT3A. Techniques included immunofluorescence, co-immunoprecipitation, glycosylation validation, CCK-8, wound healing, Transwell and flow cytometry.
resultsClinical data revealed significant downregulation of FCN3 in HCC tissues, correlating with poor patient survival. Mechanistically, FCN3 suppressed Treg activation and HCC progression by inhibiting Wnt/β-catenin signaling through APC upregulation. However, the glycosyltransferase STT3A mediated N-glycosylation of FCN3 at Asn189, thereby disrupting the tumor-suppressive function of FCN3 in HCC. In mouse models, STT3A knockdown reduced tumor growth and decreased Treg infiltration. Additionally, the Treg cell-depleting agent diphtheria toxin could reverse the promoting effect of STT3A overexpression on HCC tumor growth.
conclusionThis research unveiled a novel STT3A-FCN3-β-catenin axis that drove HCC progression through glycosylation-dependent Treg activation. These findings provided new insights into immune evasion mechanisms and highlighted potential therapeutic opportunities for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.